Biotech

Kadmon Announces Publication of Data Demonstrating the Potential of ROCK2 Inhibition to Treat Chronic Graft-Versus-Host Disease

NEW YORK, NY: Data Published in the Journal Blood Kadmon to Initiate Phase 2 Study of ROCK2 Inhibitor KD025 in cGVHD in 2016 ...

Mr. Zvika Joseph to Step Down as Chairman of the Board of Directors

JERUSALEM, ISRAEL: ...

It''s LIVE! 2016 North American Pharmaceutical & Biotech Outlook Spotlights $20 Billion Potential in Capital Spending, an Industrial Info News Alert

SUGAR LAND, TX: ...

Novimmune''s NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH)

GENEVA, SWITZERLAND: NI-0501 Is the First Treatment Developed for HLH ...

Immunovaccine Announces Management Team Changes

HALIFAX, NOVA SCOTIA: CEO Marc Mansour Resigns; CBO Frederic Ors Named Acting Chief Executive ...

Pivot Pharmaceuticals Announces Blue Sky Compliance

BOSTON, MA and VANCOUVER, BC: ...

M Pharmaceutical Announces Change to Management

VANCOUVER, BRITISH COLUMBIA: ...

IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal

SYDNEY, AUSTRALIA: ...

Choate, Hall & Stewart''s Intellectual Property Group Receives Top Rankings From Managing Intellectual Property

BOSTON, MA: ...

Flamel Technologies Reports Fourth Quarter and Full Year 2015 Results

LYON, FRANCE: Full Year Product Revenues of $173.2 Million and Diluted EPS of $0.93; Reaffirms 2016 Revenue Guidance of $110 Million to $130 Million ...